[Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] I got to run.
Turns out no policy expert says the FDA needs a one size fits all approach, or OS is the only endpoint. I don't say that either; u can double check👇 
But arbitrary RR cutoffs for 200k/yr drugs makes no sense (12% ok, but 6.7% not)
_URL_0_